;PMID: 11180166
;source_file_671.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:36..110] = [t:36..110]
;2)section:[e:114..171] = [t:114..171]
;3)section:[e:175..275] = [t:175..275]
;4)sentence:[e:279..365] = [t:279..365]
;5)sentence:[e:366..484] = [t:366..484]
;6)sentence:[e:485..703] = [t:485..703]
;7)sentence:[e:704..833] = [t:704..833]
;8)sentence:[e:834..882] = [t:834..882]
;9)sentence:[e:883..928] = [t:883..928]
;10)sentence:[e:929..1046] = [t:929..1046]
;11)sentence:[e:1048..1185] = [t:1048..1185]
;12)sentence:[e:1186..1326] = [t:1186..1326]
;13)sentence:[e:1327..1444] = [t:1327..1444]
;14)sentence:[e:1445..1649] = [t:1445..1649]
;15)section:[e:1653..1698] = [t:1653..1698]

;section 0 Span:0..31
;J Pathol  2001 Feb;193(2):193-9
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..8] Pathol) (CD:[10..14] 2001)
        (-LRB-:[15..23] Feb;193-LRB-) (CD:[23..24] 2) (-RRB-:[24..25] -RRB-)
        (CD:[25..29] :193) (::[29..30] -) (CD:[30..31] 9)))

;sentence 1 Span:36..110
;K-ras mutations in endometrial carcinomas with microsatellite instability.
;[36..41]:gene-rna:"K-ras"
;[55..77]:malignancy:"endometrial carcinomas"
(SENT
  (NP-HLN
    (NP (NN:[36..41] K-ras) (NNS:[42..51] mutations))
    (PP-LOC (IN:[52..54] in)
      (NP
        (NP (JJ:[55..66] endometrial) (NNS:[67..77] carcinomas))
        (PP (IN:[78..82] with)
          (NP (NN:[83..97] microsatellite) (NN:[98..109] instability)))))
    (.:[109..110] .)))

;section 2 Span:114..171
;Lagarda H, Catasus L, Arguelles R, Matias-Guiu X, Prat J.
(SEC
  (FRAG (NNP:[114..121] Lagarda) (NNP:[122..123] H) (,:[123..124] ,)
        (NNP:[125..132] Catasus) (NNP:[133..135] L,) (NNP:[136..145] Arguelles)
        (NNP:[146..148] R,) (NNP:[149..155] Matias) (HYPH:[155..156] -)
        (NNP:[156..160] Guiu) (NNP:[161..162] X) (,:[162..163] ,)
        (NNP:[164..168] Prat) (NNP:[169..171] J.)))

;section 3 Span:175..275
;Department of Pathology, Hospital Santa Creu i Sant Pau, Autonomous
;University  of Barcelona, Spain.
(SEC
  (FRAG (NNP:[175..185] Department) (IN:[186..188] of)
        (NNP:[189..198] Pathology) (,:[198..199] ,) (NNP:[200..208] Hospital)
        (NNP:[209..214] Santa) (NNP:[215..219] Creu) (NNP:[220..221] i)
        (NNP:[222..226] Sant) (NNP:[227..230] Pau) (,:[230..231] ,)
        (NNP:[232..242] Autonomous) (NNP:[243..253] University)
        (IN:[255..257] of) (NNP:[258..267] Barcelona) (,:[267..268] ,)
        (NNP:[269..274] Spain) (.:[274..275] .)))

;sentence 4 Span:279..365
;K-ras mutations are known to occur in hyperplasias and carcinomas of the 
;endometrium.
;[279..284]:gene-rna:"K-ras"
;[317..329]...[345..364]:malignancy:"hyperplasias"..."of the  endometrium"
;[334..364]:malignancy:"carcinomas of the  endometrium"
(SENT
  (S
    (NP-SBJ-1 (NN:[279..284] K-ras) (NNS:[285..294] mutations))
    (VP (VBP:[295..298] are)
      (VP (VBN:[299..304] known)
        (S
          (NP-SBJ-1 (-NONE-:[304..304] *))
          (VP (TO:[305..307] to)
            (VP (VB:[308..313] occur)
              (PP-LOC (IN:[314..316] in)
                (NP
                  (NP (NNS:[317..329] hyperplasias) (CC:[330..333] and)
                      (NNS:[334..344] carcinomas))
                  (PP (IN:[345..347] of)
                    (NP (DT:[348..351] the) (NN:[353..364] endometrium))))))))))
    (.:[364..365] .)))

;sentence 5 Span:366..484
;No clear correlation has been found yet between K-ras mutations and 
;microsatellite instability (MI) in these lesions.
;[414..419]:gene-rna:"K-ras"
;[476..483]:malignancy:"lesions"
(SENT
  (S
    (NP-SBJ-1 (DT:[366..368] No) (JJ:[369..374] clear)
              (NN:[375..386] correlation))
    (VP (VBZ:[387..390] has)
      (VP (VBN:[391..395] been)
        (VP (VBN:[396..401] found)
          (NP-1 (-NONE-:[401..401] *))
          (ADVP (RB:[402..405] yet))
          (PP (IN:[406..413] between)
            (NP
              (NP (NN:[414..419] K-ras) (NNS:[420..429] mutations))
              (CC:[430..433] and)
              (NP
                (NP (NN:[435..449] microsatellite) (NN:[450..461] instability))
                (NP (-LRB-:[462..463] -LRB-) (NN:[463..465] MI)
                    (-RRB-:[465..466] -RRB-)))))
          (PP-LOC (IN:[467..469] in)
            (NP (DT:[470..475] these) (NNS:[476..483] lesions))))))
    (.:[483..484] .)))

;sentence 6 Span:485..703
;Fifty-eight endometrial  carcinomas (ECs) and 22 endometrial hyperplasias
;(EHs) were analysed for K-ras  mutation by single-strand conformational
;polymorphism analysis (SSCP),  restriction analysis, and DNA sequencing.
;[497..520]:malignancy:"endometrial  carcinomas"
;[522..525]:malignancy:"ECs"
;[534..558]:malignancy:"endometrial hyperplasias"
;[560..563]:malignancy:"EHs"
;[583..588]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (CD:[485..496] Fifty-eight)
        (NML
          (NML (JJ:[497..508] endometrial) (NNS:[510..520] carcinomas))
          (NML (-LRB-:[521..522] -LRB-) (NNS:[522..525] ECs)
               (-RRB-:[525..526] -RRB-))))
      (CC:[527..530] and)
      (NP (CD:[531..533] 22)
        (NML
          (NML (JJ:[534..545] endometrial) (NNS:[546..558] hyperplasias))
          (NML (-LRB-:[559..560] -LRB-) (NNS:[560..563] EHs)
               (-RRB-:[563..564] -RRB-)))))
    (VP (VBD:[565..569] were)
      (VP (VBN:[570..578] analysed)
        (NP-1 (-NONE-:[578..578] *))
        (PP (IN:[579..582] for)
          (NP (NN:[583..588] K-ras) (NN:[590..598] mutation)))
        (PP-MNR (IN:[599..601] by)
          (NP
            (NP
              (NP
                (NML (JJ:[602..608] single) (HYPH:[608..609] -)
                     (NN:[609..615] strand))
                (JJ:[616..630] conformational) (NN:[631..643] polymorphism)
                 (NN:[644..652] analysis))
              (NP (-LRB-:[653..654] -LRB-) (NN:[654..658] SSCP)
                  (-RRB-:[658..659] -RRB-)))
            (,:[659..660] ,)
            (NP (NN:[662..673] restriction) (NN:[674..682] analysis))
            (,:[682..683] ,) (CC:[684..687] and)
            (NP (NN:[688..691] DNA) (NN:[692..702] sequencing))))))
    (.:[702..703] .)))

;sentence 7 Span:704..833
;MI status had been established  previously at five dinucleotide loci and was
;reconfirmed with markers BAT-25 and  BAT-26 by SSCP.
(SENT
  (S
    (NP-SBJ-1 (NN:[704..706] MI) (NN:[707..713] status))
    (VP
      (VP (VBD:[714..717] had)
        (VP (VBN:[718..722] been)
          (VP (VBN:[723..734] established)
            (NP-1 (-NONE-:[734..734] *))
            (ADVP-TMP (RB:[736..746] previously))
            (PP-LOC (IN:[747..749] at)
              (NP (CD:[750..754] five) (NN:[755..767] dinucleotide)
                  (NNS:[768..772] loci))))))
      (CC:[773..776] and)
      (VP (VBD:[777..780] was)
        (VP (VBN:[781..792] reconfirmed)
          (NP-1 (-NONE-:[792..792] *))
          (PP (IN:[793..797] with)
            (NP
              (NP
                (NML-2 (NNS:[798..805] markers))
                (NN:[806..812] BAT-25))
              (CC:[813..816] and)
              (NP
                (NML-2 (-NONE-:[816..816] *P*))
                (NN:[818..824] BAT-26))))
          (PP-MNR (IN:[825..827] by)
            (NP (NN:[828..832] SSCP))))))
    (.:[832..833] .)))

;sentence 8 Span:834..882
;K-ras mutations were detected in 11 ECs (18.9%).
;[834..839]:gene-rna:"K-ras"
;[870..873]:malignancy:"ECs"
(SENT
  (S
    (NP-SBJ-1 (NN:[834..839] K-ras) (NNS:[840..849] mutations))
    (VP (VBD:[850..854] were)
      (VP (VBN:[855..863] detected)
        (NP-1 (-NONE-:[863..863] *))
        (PP-LOC (IN:[864..866] in)
          (NP (CD:[867..869] 11) (NNS:[870..873] ECs)))
        (PRN (-LRB-:[874..875] -LRB-)
          (NP (CD:[875..879] 18.9) (NN:[879..880] %))
          (-RRB-:[880..881] -RRB-))))
    (.:[881..882] .)))

;sentence 9 Span:883..928
;All 11 tumours  were endometrioid carcinomas.
;[890..897]:malignancy:"tumours"
;[904..927]:malignancy:"endometrioid carcinomas"
(SENT
  (S
    (NP-SBJ (DT:[883..886] All) (CD:[887..889] 11) (NNS:[890..897] tumours))
    (VP (VBD:[899..903] were)
      (NP-PRD (JJ:[904..916] endometrioid) (NNS:[917..927] carcinomas)))
    (.:[927..928] .)))

;sentence 10 Span:929..1046
;K-ras mutations were more frequent in MI-positive  (6/14, 42.8%) than in
;MI-negative tumours (5/44, 11.3%) (p=0.017).
;[929..934]:gene-rna:"K-ras"
;[967..978]...[1014..1021]:malignancy:"MI-positive"..."tumours"
;[1002..1021]:malignancy:"MI-negative tumours"
(SENT
  (S
    (NP-SBJ (NN:[929..934] K-ras) (NNS:[935..944] mutations))
    (VP (VBD:[945..949] were)
      (ADJP-PRD
        (ADJP (RBR:[950..954] more) (JJ:[955..963] frequent))
        (PP (IN:[964..966] in)
          (NP (NN:[967..969] MI) (HYPH:[969..970] -) (JJ:[970..978] positive)
            (PRN (-LRB-:[980..981] -LRB-)
              (FRAG
                (NP
                  (NP (CD:[981..982] 6))
                  (PP (SYM:[982..983] /)
                    (NP (CD:[983..985] 14))))
                (,:[985..986] ,)
                (NP (CD:[987..991] 42.8) (NN:[991..992] %)))
              (-RRB-:[992..993] -RRB-))))
        (PP (IN:[994..998] than)
          (PP (IN:[999..1001] in)
            (NP
              
              (NML (NN:[1002..1004] MI) (HYPH:[1004..1005] -)
                   (JJ:[1005..1013] negative))
              (NNS:[1014..1021] tumours)
              (PRN (-LRB-:[1022..1023] -LRB-)
                (FRAG
                  (NP
                    (NP (CD:[1023..1024] 5))
                    (PP (SYM:[1024..1025] /)
                      (NP (CD:[1025..1027] 44))))
                  (,:[1027..1028] ,)
                  (NP (CD:[1029..1033] 11.3) (NN:[1033..1034] %)))
                (-RRB-:[1034..1035] -RRB-)))))
        (PRN (-LRB-:[1036..1037] -LRB-)
          (S
            (NP-SBJ (NN:[1037..1038] p))
            (VP (SYM:[1038..1039] =)
              (NP (CD:[1039..1044] 0.017))))
          (-RRB-:[1044..1045] -RRB-))))
    (.:[1045..1046] .)))

;sentence 11 Span:1048..1185
;Methylation-related transitions were detected in five of the six MI-positive 
;tumours but in only one of the five MI-negative carcinomas.
;[1113..1133]:malignancy:"MI-positive  tumours"
;[1162..1184]:malignancy:"MI-negative carcinomas"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1048..1059] Methylation) (HYPH:[1059..1060] -)
          (VBN:[1060..1067] related))
      (NNS:[1068..1079] transitions))
    (VP (VBD:[1080..1084] were)
      (VP (VBN:[1085..1093] detected)
        (NP-1 (-NONE-:[1093..1093] *))
        (PP
          (PP (IN:[1094..1096] in)
            (NP
              (NP (CD:[1097..1101] five))
              (PP (IN:[1102..1104] of)
                (NP (DT:[1105..1108] the) (CD:[1109..1112] six)
                  
                  (NP (NN:[1113..1115] MI) (HYPH:[1115..1116] -)
                      (JJ:[1116..1124] positive))
                  (NNS:[1126..1133] tumours)))))
          (CC:[1134..1137] but)
          (PP (IN:[1138..1140] in)
            (NP
              (NP (RB:[1141..1145] only) (CD:[1146..1149] one))
              (PP (IN:[1150..1152] of)
                (NP (DT:[1153..1156] the) (CD:[1157..1161] five)
                  
                  (NML (NN:[1162..1164] MI) (HYPH:[1164..1165] -)
                       (JJ:[1165..1173] negative))
                  (NNS:[1174..1184] carcinomas))))))))
    (.:[1184..1185] .)))

;sentence 12 Span:1186..1326
;K-ras mutation was  identified in only one atypical EH (1/22, 4.5%); in this
;case, the EH co-existed  with EC and both lesions exhibited MI.
;[1186..1191]:gene-rna:"K-ras"
;[1229..1240]:malignancy:"atypical EH"
;[1273..1275]:malignancy:"EH"
;[1293..1295]:malignancy:"EC"
;[1305..1312]:malignancy:"lesions"
(SENT
  (S
    (S
      (NP-SBJ-1 (NN:[1186..1191] K-ras) (NN:[1192..1200] mutation))
      (VP (VBD:[1201..1204] was)
        (VP (VBN:[1206..1216] identified)
          (NP-1 (-NONE-:[1216..1216] *))
          (PP-LOC (IN:[1217..1219] in)
            (NP (RB:[1220..1224] only) (CD:[1225..1228] one)
               (JJ:[1229..1237] atypical) (NN:[1238..1240] EH)
              (PRN (-LRB-:[1241..1242] -LRB-)
                (FRAG
                  (NP
                    (NP (CD:[1242..1243] 1))
                    (PP (SYM:[1243..1244] /)
                      (NP (CD:[1244..1246] 22))))
                  (,:[1246..1247] ,)
                  (NP (CD:[1248..1251] 4.5) (NN:[1251..1252] %)))
                (-RRB-:[1252..1253] -RRB-)))))))
    (::[1253..1254] ;)
    (S
      (S
        (PP (IN:[1255..1257] in)
          (NP (DT:[1258..1262] this) (NN:[1263..1267] case)))
        (,:[1267..1268] ,)
        (NP-SBJ (DT:[1269..1272] the) (NN:[1273..1275] EH))
        (VP (AFX:[1276..1278] co) (HYPH:[1278..1279] -)
            (VBD:[1279..1286] existed)
          (PP (IN:[1288..1292] with)
            (NP (NN:[1293..1295] EC)))))
      (CC:[1296..1299] and)
      (S
        (NP-SBJ (DT:[1300..1304] both) (NNS:[1305..1312] lesions))
        (VP (VBD:[1313..1322] exhibited)
          (NP (NN:[1323..1325] MI)))))
    (.:[1325..1326] .)))

;sentence 13 Span:1327..1444
;The results support a close relationship  between K-ras mutations and the
;phenomenon of MI in endometrial carcinomas.
;[1377..1382]:gene-rna:"K-ras"
;[1421..1443]:malignancy:"endometrial carcinomas"
(SENT
  (S
    (NP-SBJ (DT:[1327..1330] The) (NNS:[1331..1338] results))
    (VP (VBP:[1339..1346] support)
      (NP
        (NP (DT:[1347..1348] a) (JJ:[1349..1354] close)
            (NN:[1355..1367] relationship))
        (PP (IN:[1369..1376] between)
          (NP
            (NP
              (NP (NN:[1377..1382] K-ras) (NNS:[1383..1392] mutations))
              (CC:[1393..1396] and)
              (NP
                (NP (DT:[1397..1400] the) (NN:[1401..1411] phenomenon))
                (PP (IN:[1412..1414] of)
                  (NP (NN:[1415..1417] MI)))))
            (PP-LOC (IN:[1418..1420] in)
              (NP (JJ:[1421..1432] endometrial) (NNS:[1433..1443] carcinomas)))))))
    (.:[1443..1444] .)))

;sentence 14 Span:1445..1649
;The  frequent occurrence of methylation-related transitions in these tumours
;may  indicate a cause-effect relationship with the altered methylation status
;which  has been described in association with MI.
;[1514..1521]:malignancy:"tumours"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1445..1448] The) (JJ:[1450..1458] frequent)
          (NN:[1459..1469] occurrence))
      (PP (IN:[1470..1472] of)
        (NP
          (ADJP (NN:[1473..1484] methylation) (HYPH:[1484..1485] -)
                (VBN:[1485..1492] related))
          (NNS:[1493..1504] transitions)))
      (PP-LOC (IN:[1505..1507] in)
        (NP (DT:[1508..1513] these) (NNS:[1514..1521] tumours))))
    (VP (MD:[1522..1525] may)
      (VP (VB:[1527..1535] indicate)
        (NP
          (NP (DT:[1536..1537] a)
            (NML (NN:[1538..1543] cause) (HYPH:[1543..1544] -)
                 (NN:[1544..1550] effect))
            (NN:[1551..1563] relationship))
          (PP (IN:[1564..1568] with)
            (NP
              (NP (DT:[1569..1572] the) (VBN:[1573..1580] altered)
                  (NN:[1581..1592] methylation) (NN:[1593..1599] status))
              (SBAR
                (WHNP-1 (WDT:[1600..1605] which))
                (S
                  (NP-SBJ-1 (-NONE-:[1605..1605] *T*))
                  (VP (VBZ:[1607..1610] has)
                    (VP (VBN:[1611..1615] been)
                      (VP (VBN:[1616..1625] described)
                        (NP-1 (-NONE-:[1625..1625] *))
                        (PP (IN:[1626..1628] in)
                          (NP
                            (NP (NN:[1629..1640] association))
                            (PP (IN:[1641..1645] with)
                              (NP (NN:[1646..1648] MI)))))))))))))))
    (.:[1648..1649] .)))

;section 15 Span:1653..1698
;PMID: 11180166 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1653..1657] PMID) (::[1657..1658] :) (CD:[1659..1667] 11180166)
        (-LRB-:[1668..1669] -LSB-) (NNP:[1669..1675] PubMed)
        (HYPH:[1676..1677] -) (JJ:[1678..1685] indexed) (IN:[1686..1689] for)
        (NNP:[1690..1697] MEDLINE) (-RRB-:[1697..1698] -RSB-)))
